Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report

Key Points

• Molecular devolution was observed in a chronic myelomonocytic leukemia case during therapy.
• Significant changes in biomarkers were noted after the decitabine treatment.
• Observational analysis documented the effects of decitabine and cedazuridine on leukemia progression.
• The findings underscore the need for ongoing monitoring to assess treatment impacts in chronic myelomonocytic leukemia.